Published in J Gastrointest Oncol on February 01, 2017
Bias in meta-analysis detected by a simple, graphical test. BMJ (1997) 122.24
Cancer statistics, 2014. CA Cancer J Clin (2014) 72.81
Operating characteristics of a rank correlation test for publication bias. Biometrics (1994) 47.97
THE TWO HISTOLOGICAL MAIN TYPES OF GASTRIC CARCINOMA: DIFFUSE AND SO-CALLED INTESTINAL-TYPE CARCINOMA. AN ATTEMPT AT A HISTO-CLINICAL CLASSIFICATION. Acta Pathol Microbiol Scand (1965) 22.65
Trim and fill: A simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. Biometrics (2000) 19.26
Comprehensive molecular characterization of gastric adenocarcinoma. Nature (2014) 11.93
Nodal dissection for patients with gastric cancer: a randomised controlled trial. Lancet Oncol (2006) 4.38
Postoperative nomogram for disease-specific survival after an R0 resection for gastric carcinoma. J Clin Oncol (2003) 3.56
Transcription factor Sp1 expression is a significant predictor of survival in human gastric cancer. Clin Cancer Res (2003) 2.38
Intrinsic subtypes of gastric cancer, based on gene expression pattern, predict survival and respond differently to chemotherapy. Gastroenterology (2011) 2.36
Molecular classification of gastric cancer: a new paradigm. Clin Cancer Res (2011) 2.00
Epigenetic silencing of cyclooxygenase-2 affects clinical outcome in gastric cancer. J Clin Oncol (2007) 1.97
Tumour suppressor gene expression correlates with gastric cancer prognosis. J Pathol (2003) 1.86
Association between expression of transcription factor Sp1 and increased vascular endothelial growth factor expression, advanced stage, and poor survival in patients with resected gastric cancer. Clin Cancer Res (2004) 1.84
Elevated preoperative neutrophil to lymphocyte ratio predicts poor survival following resection in late stage gastric cancer. J Surg Oncol (2011) 1.84
Role of the extended lymphadenectomy in gastric cancer surgery: experience in a single institution. Ann Surg Oncol (2003) 1.76
Expression of activated signal transducer and activator of transcription 3 predicts expression of vascular endothelial growth factor in and angiogenic phenotype of human gastric cancer. Clin Cancer Res (2005) 1.57
Prognosis of metastatic gastric and gastroesophageal junction cancer by HER2 status: a European and USA International collaborative analysis. Ann Oncol (2012) 1.55
Different patterns of recurrence in gastric cancer depending on Lauren's histological type: longitudinal study. World J Surg (2002) 1.50
High expression of HER3 is associated with a decreased survival in gastric cancer. Clin Cancer Res (2008) 1.38
MET overexpression assessed by new interpretation method predicts gene amplification and poor survival in advanced gastric carcinomas. Mod Pathol (2013) 1.25
Expression of NDRG2 is related to tumor progression and survival of gastric cancer patients through Fas-mediated cell death. Exp Mol Med (2007) 1.24
Association between polymorphisms in interleukin-17A and interleukin-17F genes and risks of gastric cancer. Int J Cancer (2010) 1.21
Impact of insulin-like growth factor type 1 receptor, epidermal growth factor receptor, and HER2 expressions on outcomes of patients with gastric cancer. Clin Cancer Res (2008) 1.19
Long-term survivors of gastric cancer: a California population-based study. J Clin Oncol (2012) 1.16
Metastatic lymph node ratio as a prognostic factor in gastric cancer. Eur J Surg Oncol (2005) 1.15
Survival and surgical outcomes after laparoscopy-assisted total gastrectomy for gastric cancer: case-control study. Surg Endosc (2012) 1.12
Clinicopathologic and protein expression differences between cardia carcinoma and noncardia carcinoma of the stomach. Cancer (2005) 1.11
Prognostic implications of the seventh edition of the international union against cancer classification for patients with gastric cancer: the Western experience of patients treated in a single-center European institution. J Clin Oncol (2012) 1.09
A review on biomarkers for prediction of treatment outcome in gastric cancer. Anticancer Res (2013) 1.09
HER2/neu testing for anti-HER2-based therapies in patients with unresectable and/or metastatic gastric cancer. J Clin Pathol (2012) 1.09
Efficacy of trastuzumab in Japanese patients with HER2-positive advanced gastric or gastroesophageal junction cancer: a subgroup analysis of the Trastuzumab for Gastric Cancer (ToGA) study. Gastric Cancer (2011) 1.08
Prognostic significance of perineural invasion in patients with gastric cancer who underwent curative resection. Ann Surg Oncol (2010) 1.08
HER2 screening data from ToGA: targeting HER2 in gastric and gastroesophageal junction cancer. Gastric Cancer (2014) 1.05
Impact of HER-2 overexpression/amplification on the prognosis of gastric cancer patients undergoing resection: a single-center study of 1,036 patients. Oncologist (2011) 1.04
Downregulation of tumor suppressor QKI in gastric cancer and its implication in cancer prognosis. Biochem Biophys Res Commun (2012) 1.03
Combined evaluation of expressions of cyclin E and p53 proteins as prognostic factors for patients with gastric cancer. Clin Cancer Res (2005) 1.01
Snail is an independent prognostic predictor for progression and patient survival of gastric cancer. Cancer Sci (2012) 1.01
Proposal for a multifactorial prognostic score that accurately classifies 3 groups of gastric carcinoma patients with different outcomes after neoadjuvant chemotherapy and surgery. Ann Surg (2012) 1.01
Implications of overweight in gastric cancer: A multicenter study in a Western patient population. Eur J Surg Oncol (2010) 1.00
Multicenter large-scale study of prognostic impact of HER2 expression in patients with resectable gastric cancer. Gastric Cancer (2014) 1.00
Clinicopathologic significance of ERCC1, thymidylate synthase and glutathione S-transferase P1 expression for advanced gastric cancer patients receiving adjuvant 5-FU and cisplatin chemotherapy. Biomarkers (2010) 0.98
The prognostic impact of epidermal growth factor receptor in patients with metastatic gastric cancer. BMC Cancer (2012) 0.98
Vimentin expression is associated with decreased survival in gastric cancer. Oncol Rep (2011) 0.98
Comparison of the 6th and 7th editions of the AJCC/UICC TNM staging system for gastric cancer focusing on the "N" parameter-related survival: the monoinstitutional NodUs Italian study. World J Surg Oncol (2015) 0.96
Prognostic significance of lymphovascular invasion in node-negative gastric cancer. World J Surg (2015) 0.95
Clinical significance of SOD2 and GSTP1 gene polymorphisms in Chinese patients with gastric cancer. Cancer (2012) 0.91
Perigastric tumor deposits in primary gastric cancer: implications for patient prognosis and staging. Ann Surg Oncol (2012) 0.91
Lauren classification combined with HER2 status is a better prognostic factor in Chinese gastric cancer patients. BMC Cancer (2014) 0.90
Osteopontin, E-cadherin, and β-catenin expression as prognostic biomarkers in patients with radically resected gastric cancer. Gastric Cancer (2015) 0.89
Does tumor size have an impact on gastric cancer? A single institute experience. Langenbecks Arch Surg (2008) 0.89
Prognostic factor analysis of third-line chemotherapy in patients with advanced gastric cancer. Gastric Cancer (2011) 0.89
Unchanged survival of gastric cancer in the southeastern Netherlands since 1982: result of differential trends in incidence according to Laurén type and subsite. Int J Cancer (1999) 0.88
Is gastric cancer different in Korea and the United States? Impact of tumor location on prognosis. Ann Surg Oncol (2014) 0.88
Hypermethylation of tumor-related genes in Tunisian patients with gastric carcinoma: clinical and biological significance. J Surg Oncol (2011) 0.88
Clinical evidence for three distinct gastric cancer subtypes: time for a new approach. PLoS One (2013) 0.88
MDM2 is a useful prognostic biomarker for resectable gastric cancer. Cancer Sci (2013) 0.87
TNK2 gene amplification is a novel predictor of a poor prognosis in patients with gastric cancer. J Surg Oncol (2013) 0.86
Survival prolongation after treatment failure of first-line chemotherapy in patients with advanced gastric cancer: combined analysis of the Japan Clinical Oncology group trials JCOG9205 and JCOG9912. Gastric Cancer (2013) 0.85
Posttherapy nodal status, not graded histologic response, predicts survival after neoadjuvant chemotherapy for advanced gastric cancer. Ann Surg Oncol (2011) 0.85
Clinical significance of POU5F1P1 rs10505477 polymorphism in Chinese gastric cancer patients receving cisplatin-based chemotherapy after surgical resection. Int J Mol Sci (2014) 0.84
Prognostic value of tumor size in gastric cancer: an analysis of 2,379 patients. Tumour Biol (2013) 0.84
A cohort study and meta-analysis between histopathological classification and prognosis of gastric carcinoma. Anticancer Agents Med Chem (2013) 0.84
Expression of group IIA phospholipase A2 is an independent predictor of favorable outcome for patients with gastric cancer. Hum Pathol (2013) 0.84
FGFR2 Assessment in Gastric Cancer Using Quantitative Real-Time Polymerase Chain Reaction, Fluorescent In Situ Hybridization, and Immunohistochemistry. Am J Clin Pathol (2015) 0.83
Adjuvant chemotherapy for gastric cancer: current evidence and future challenges. World J Gastroenterol (2014) 0.82
Clinicopathological Features of Upper Third Gastric Cancer during a 21-Year Period (Single Center Analysis). J Gastric Cancer (2010) 0.82
Tumor size as a recommendable variable for accuracy of the prognostic prediction of gastric cancer: a retrospective analysis of 1,521 patients. Ann Surg Oncol (2014) 0.82
Overexpression of Ras-GTPase-activating protein SH3 domain-binding protein 1 correlates with poor prognosis in gastric cancer patients. Histopathology (2015) 0.82
Surgical treatment results of intestinal and diffuse type gastric cancer. Implications for a differentiated therapeutic approach? Eur J Surg Oncol (2013) 0.81
Absence of RKIP expression is an independent prognostic biomarker for gastric cancer patients. Oncol Rep (2012) 0.80
Lymphoepithelioma-like carcinoma: a distinct type of gastric cancer. J Surg Res (2014) 0.80
Short-term and long-term risk factors in gastric cancer. World J Gastroenterol (2015) 0.80
Correlation between loss of E-cadherin expression and overexpression of autocrine motility factor receptor in association with progression of human gastric cancers. Am J Clin Pathol (2000) 0.80
The prognosis of gastric cardia cancer after R0 resection. Am J Surg (2009) 0.79
Biological markers as a predictor for response and prognosis of unresectable gastric cancer patients treated with irinotecan and cisplatin. Jpn J Clin Oncol (2005) 0.79
Trends in clinical features, postoperative outcomes, and long-term survival for gastric cancer: a Western experience with 1,278 patients over 30 years. World J Surg Oncol (2014) 0.79
Clinicopathologic significance of nuclear factor-κB and vascular endothelial growth factor expression in advanced gastric cancer patients. Oncol Res Treat (2014) 0.79
Effect of preoperative chemoradiotherapy on outcome of patients with locally advanced esophagogastric junction adenocarcinoma-a pilot study. Curr Oncol (2014) 0.78
The prognostic significance of the mucin phenotype of gastric adenocarcinoma and its relationship with histologic classifications. Oncol Rep (2009) 0.78
Angiogenin in sera as an independent prognostic factor in gastric cancer. J Cancer Res Clin Oncol (2003) 0.78
Expression of pyruvate dehydrogenase is an independent prognostic marker in gastric cancer. World J Gastroenterol (2015) 0.77
Angiogenesis inhibitors in gastric and gastroesophageal junction cancer. Gastric Cancer (2015) 0.76
Overexpression of phosphorylated 4E-binding protein 1 and its clinicopathological significances in gastric cancer. Pathol Res Pract (2015) 0.76
Overexpression of the chemokine receptor CXCR3 and its correlation with favorable prognosis in gastric cancer. Hum Pathol (2015) 0.76
Log-normal censored regression model detecting prognostic factors in gastric cancer: a study of 3018 cases. World J Gastroenterol (2011) 0.76
Postoperative nodal status and diffuse-type histology are independent prognostic factors in resectable advanced gastric carcinomas after preoperative chemotherapy. Am J Surg Pathol (2013) 0.76
Does adjuvant chemoradiotherapy improve the prognosis of gastric cancer after an r1 resection? Results from a dutch cohort study. Ann Surg Oncol (2014) 0.75
Nivolumab in the treatment of advanced renal cell carcinoma: clinical trial evidence and experience. Ther Adv Urol (2016) 0.97
Prognostic Survival Associated With Left-Sided vs Right-Sided Colon Cancer: A Systematic Review and Meta-analysis. JAMA Oncol (2016) 0.96
MET-Driven Resistance to Dual EGFR and BRAF Blockade May Be Overcome by Switching from EGFR to MET Inhibition in BRAF-Mutated Colorectal Cancer. Cancer Discov (2016) 0.89
BRAF-mutated metastatic colorectal cancer between past and future. Br J Cancer (2015) 0.88
Gain of ALK gene copy number may predict lack of benefit from anti-EGFR treatment in patients with advanced colorectal cancer and RAS-RAF-PI3KCA wild-type status. PLoS One (2014) 0.87
DPD and UGT1A1 deficiency in colorectal cancer patients receiving triplet chemotherapy with fluoropyrimidines, oxaliplatin and irinotecan. Br J Clin Pharmacol (2015) 0.80
Bevacizumab-based neoadjuvant chemotherapy for colorectal cancer liver metastases: Pitfalls and helpful tricks in a review for clinicians. Crit Rev Oncol Hematol (2015) 0.78
A new nomogram for estimating survival in patients with brain metastases secondary to colorectal cancer. Radiother Oncol (2015) 0.77
Digital PCR assessment of MGMT promoter methylation coupled with reduced protein expression optimises prediction of response to alkylating agents in metastatic colorectal cancer patients. Eur J Cancer (2016) 0.77
Single-Agent Panitumumab in Frail Elderly Patients With Advanced RAS and BRAF Wild-Type Colorectal Cancer: Challenging Drug Label to Light Up New Hope. Oncologist (2015) 0.75
Editorial on role of p53 in esophageal cancer from a meta-analysis of 16 studies by Fisher et al. J Thorac Dis (2017) 0.75
Gastrointestinal tract carcinoma in pediatric and adolescent age: The Italian TREP project experience. Pediatr Blood Cancer (2017) 0.75
Preoperative Capecitabine, Oxaliplatin, and Irinotecan in Resectable Gastric or Gastroesophageal Junction Cancer: Pathological Response as Primary Endpoint and FDG-PET Predictions. Oncology (2017) 0.75
Surrogate Endpoints in Second-Line Trials of Targeted Agents in Metastatic Colorectal Cancer: A Literature-Based Systematic Review and Meta-Analysis. Cancer Res Treat (2016) 0.75
Prognostic Role of Primary Tumor Location in Non-Metastatic Gastric Cancer: A Systematic Review and Meta-Analysis of 50 Studies. Ann Surg Oncol (2017) 0.75
Perioperative Triplet Chemotherapy and Cetuximab in Patients With RAS Wild Type High Recurrence Risk or Borderline Resectable Colorectal Cancer Liver Metastases. Clin Colorectal Cancer (2016) 0.75